|Bid||17.00 x 1400|
|Ask||22.05 x 1100|
|Day's Range||21.90 - 22.58|
|52 Week Range||18.98 - 36.95|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 01, 2022 - Aug 05, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.33|
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio